---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021096"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:30:42.995093+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains

## Summary
- Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.
- Stockholders' equity as of March 31, 2024 was $6,481,856.
- Minimum bid price deficiency under Nasdaq Rule 5550(a)(2) remains outstanding.
- Company intends to monitor bid price and consider available options to resolve the deficiency.

## SEC filing metadata
- accession: 0001493152-24-021096
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224021096/0001493152-24-021096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224021096/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021096
- JSON: https://secwatch.observer/filing/0001493152-24-021096.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.